eClinical firm YPrime secures ‘significant’ PE investment

By Melissa Fassbender contact

- Last updated on GMT

(Image: Getty/pichet_w)
(Image: Getty/pichet_w)

Related tags: eclinical, Private equity, eCOA, IRT, Data collection, YPrime

The cloud-based eClinical solutions company today announced that it has received a significant investment from Flexpoint Ford, a Chicago-based private equity (PE) firm.

Founded in 2006, Malvern, PA-headquartered YPrime provides software solutions and consulting services to support collaborative clinical trial data collection and information management.

The company’s eClinical suite includes electronic clinical outcome assessments (eCOA) and interactive response technology (IRT).

Shawn Blackburn, co-founder and CEO of YPrime, said, “The investment funds will be used to support expansion with our geographic footprint as well as our product and service portfolio.”

YPrime’s current management team will retain a substantial ownership stake and continue to lead the company, which will operate independently.

“It was important for YPrime to find a partner with similar values and vision, and we found that in Flexpoint,” ​Blackburn told us.

Ballast Point Ventures (BPV), based in Tampa, FL, has backed YPrime since 2013 and will retain a minority stake in the company. 

Related news

Show more

Related products

show more

Overcoming Challenges of Clinical Data Review

Overcoming Challenges of Clinical Data Review

PerkinElmer | 10-Jun-2021 | Technical / White Paper

Clinical data review is intrinsic to clinical development, assuring patient safety, determining drug efficacy, and assessing data quality. It involves...

How clinical trial software can optimize trials

How clinical trial software can optimize trials

Formedix | 09-Jun-2021 | Technical / White Paper

This article explains the different types of clinical trial software available, and how it can be used to optimize the end to end clinical trials design...

Transforming Clinical Development

Transforming Clinical Development

PerkinElmer | 01-Jun-2021 | Technical / White Paper

The estimated cost of bringing a drug to market in the U.S. according to JAMA is $1 billion.1 The extreme cost of clinical trials urge biopharmaceutical,...

Related suppliers

Follow us

Products

View more

Webinars